Abstract
Baricitinib (BARI), an oral selective Janus kinase (JAK)1/JAK2 inhibitor, was evaluated in adult patients with moderate-to-severe atopic dermatitis (AD) who were intolerant or inadequate responders to topical therapy in the US- and Canadian-based placebo (PBO)-controlled Phase 3 trial, BREEZE-AD5 (NCT03435081). The objective of this analysis was to assess the onset and magnitude of changes across all disease dimensions (clinician-based and patient-reported outcomes) for the first 4 weeks of treatment in this monotherapy trial. Patients (N = 440) were randomized 1:1:1 to once-daily PBO or BARI (1-mg or 2-mg). At baseline, topical and systemic AD therapies were not allowed but could be used for rescue; data after rescue or discontinuation were considered missing. Least-squares mean change from baseline to Week 1 through Week 4 were compared between treatments using mixed model repeated measure analysis for the following: Eczema Area and Severity Index (EASI), Itch Numeric Rating Scale (NRS), Skin Pain NRS, AD Sleep Scale (ADSS) Item 2 (frequency of nighttime awakenings), Dermatology Life Quality Index (DLQI), and Patient Oriented Eczema Measure (POEM). Statistically significant improvements (P ˂ .05) in EASI, Itch NRS, Skin Pain NRS, ADSS Item 2, POEM, and DLQI were observed by Week 1 for both BARI doses compared with PBO. Statistically significant improvements (P ˂ .05) were maintained to Week 4 for both BARI doses, except with BARI 1 mg vs PBO for ADSS Item 2 (P = .055). BARI resulted in rapid and concurrent improvements in EASI, itch, sleep disturbance, DLQI, and POEM, with statistically significant improvements seen by Week 1.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call